
Amphastar Pharmaceuticals AMPH
$ 20.36
2.0%
Annual report 2025
added 02-26-2026
Amphastar Pharmaceuticals Depreciation & Amortization 2011-2026 | AMPH
Annual Depreciation & Amortization Amphastar Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 31.6 M | 28.2 M | 25.2 M | 23.8 M | 10.2 M | 9.03 M | 7.06 M | 6.05 M | 6.42 M | 12.2 M | 11.3 M | 12.5 M | 11.2 M | 9.66 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 31.6 M | 6.05 M | 14.6 M |
Quarterly Depreciation & Amortization Amphastar Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.1 M | 14.6 M | 7.37 M | - | 13.4 M | 13.1 M | 6.82 M | - | 9.62 M | 3.06 M | 3.4 M | - | 3.42 M | 3 M | 2.74 M | - | 2.5 M | 2.64 M | 2.48 M | - | 2.46 M | 2.03 M | 2.05 M | - | 1.7 M | 1.66 M | 1.64 M | - | 10.4 M | 6.51 M | 3.06 M | - | 9.67 M | 6.24 M | 3.1 M | - | 9.01 M | 6 M | 2.95 M | - | 8.52 M | 5.63 M | 2.77 M | - | 9.24 M | 6.04 M | 2.94 M | - | 8.19 M | 5.4 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 14.6 M | 1.64 M | 5.78 M |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
NextCure
NXTC
|
2.2 M | $ 12.67 | 0.52 % | $ 354 M | ||
|
Liquidia Corporation
LQDA
|
1.53 M | $ 34.25 | -0.38 % | $ 2.23 B | ||
|
Shattuck Labs
STTK
|
3.7 M | $ 5.02 | 6.13 % | $ 214 M | ||
|
Acorda Therapeutics
ACOR
|
31.7 M | - | -24.86 % | $ 820 K | ||
|
I-Mab
IMAB
|
23.9 M | - | - | $ 866 M | ||
|
AbCellera Biologics
ABCL
|
18.4 M | $ 3.58 | -1.38 % | $ 1.07 B | ||
|
Acer Therapeutics
ACER
|
66 K | - | 2.71 % | $ 14 M | ||
|
ADMA Biologics
ADMA
|
8 M | $ 15.57 | -5.89 % | $ 3.71 B | ||
|
AgeX Therapeutics
AGE
|
131 K | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.51 M | - | - | $ 26.5 M | ||
|
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | ||
|
Aptorum Group Limited
APM
|
1.13 M | $ 0.82 | -0.73 % | $ 4.47 M | ||
|
Akouos
AKUS
|
2.49 M | - | 0.23 % | $ 488 M | ||
|
Alpine Immune Sciences
ALPN
|
597 K | - | - | $ 2.17 B | ||
|
AlloVir
ALVR
|
398 K | - | 4.14 % | $ 49.1 M | ||
|
Adverum Biotechnologies
ADVM
|
3.65 M | - | - | $ 86.2 M | ||
|
Ampio Pharmaceuticals
AMPE
|
122 K | - | -11.43 % | $ 502 K | ||
|
Anika Therapeutics
ANIK
|
6.43 M | $ 14.19 | -1.18 % | $ 208 M | ||
|
ANI Pharmaceuticals
ANIP
|
67.7 M | $ 75.6 | -1.22 % | $ 1.46 B | ||
|
Apellis Pharmaceuticals
APLS
|
1.56 M | $ 20.24 | 1.91 % | $ 2.55 B | ||
|
Aravive
ARAV
|
886 K | - | -13.39 % | $ 1.45 M | ||
|
ARCA biopharma
ABIO
|
27 K | - | 1052.0 % | $ 415 M | ||
|
Athersys
ATHX
|
1.43 M | - | 3.77 % | $ 22.4 M | ||
|
Autolus Therapeutics plc
AUTL
|
7.55 M | $ 1.5 | -8.28 % | $ 383 M | ||
|
AVEO Pharmaceuticals
AVEO
|
67 K | - | - | $ 521 M | ||
|
Axsome Therapeutics
AXSM
|
503 K | $ 159.87 | -2.57 % | $ 7.95 B | ||
|
BridgeBio Pharma
BBIO
|
5.43 M | $ 65.73 | -1.22 % | $ 12.6 B | ||
|
Acasti Pharma
ACST
|
7 K | - | 4.01 % | $ 150 M | ||
|
Brainstorm Cell Therapeutics
BCLI
|
240 K | - | -2.5 % | $ 5.88 M | ||
|
BioDelivery Sciences International
BDSI
|
140 K | - | -4.8 % | $ 255 M | ||
|
BeiGene, Ltd.
BGNE
|
142 M | - | 0.49 % | $ 251 B | ||
|
Bellicum Pharmaceuticals
BLCM
|
11 K | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
9 M | - | -7.31 % | $ 87 M | ||
|
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M | ||
|
BioMarin Pharmaceutical
BMRN
|
79.6 M | $ 60.54 | 0.18 % | $ 11.6 B | ||
|
CymaBay Therapeutics
CBAY
|
681 K | - | - | $ 3.45 B | ||
|
Codexis
CDXS
|
4.95 M | $ 1.25 | 16.2 % | $ 91.8 M | ||
|
Cabaletta Bio
CABA
|
1.43 M | $ 3.2 | -6.71 % | $ 3.74 M |